BiotechTube

Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide.

Phase 3Recruiting
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Advanced Gastroenteropancreatic Neuroendocrine Tumor

Conditions

Advanced Gastroenteropancreatic Neuroendocrine Tumor

Trial Timeline

Jul 6, 2023 → Oct 1, 2030

NCT ID
NCT05884255

About Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide.

Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide. is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Advanced Gastroenteropancreatic Neuroendocrine Tumor. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05884255. Target conditions include Advanced Gastroenteropancreatic Neuroendocrine Tumor.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT05884255Phase 3Recruiting

Competing Products

20 competing products in Advanced Gastroenteropancreatic Neuroendocrine Tumor

See all competitors
ProductCompanyStageHype Score
AK-105AkesoPhase 1
32
AFM24 + Atezolizumab 840 MG in 14 ML InjectionAffimedPhase 1/2
33
EXS21546BiotrialPhase 1/2
33
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)Syros PharmaceuticalsPhase 1
25
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
52
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
52
NBTXR3NanobiotixPhase 1/2
36
pegfilgrastim + LY2523355Eli LillyPhase 1
33
SON-1010Sonnet BioTherapeuticsPhase 1
28
SON-1010Sonnet BioTherapeuticsPhase 1/2
36
BT1718Bicycle TherapeuticsPhase 1/2
33
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
44
IMC-18F1Eli LillyPhase 1
33
Tadalafil + GemcitabineEli LillyPhase 1
33
OKI-179OnKure TherapeuticsPhase 1
25
OKI-219 + Fulvestrant + Trastuzumab + Tucatinib + Atirmociclib + RibociclibOnKure TherapeuticsPhase 1
25
LY3499446 + Abemaciclib + Cetuximab + Erlotinib + DocetaxelEli LillyPhase 1/2
41
LY3434172Eli LillyPhase 1
33
ACR-2316Acrivon TherapeuticsPhase 1
25
BBP-398LianBioPhase 1
25

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85